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Development of Non-Hydrolysable Oligosaccharide
Activity-Based Inactivators for Endoglycanases: A Case
Study on α-1,6 Mannanases
Sybrin P. Schröder+,[a] Wendy A. Offen+,[b] Alexandra Males,[b] Yi Jin,[b] Casper de Boer,[a]
Jacopo Enotarpi,[a] Laura Marino,[a] Gijsbert A. van der Marel,[a] Bogdan I. Florea,[a]
Jeroen D. C. Codée,[a] Herman S. Overkleeft,*[a] and Gideon J. Davies*[b]
Abstract: There is a vast genomic resource for enzymes
active on carbohydrates. Lagging far behind, however, are
functional chemical tools for the rapid characterization of
carbohydrate-active enzymes. Activity-based probes (ABPs)
offer one chemical solution to these issues with ABPs based
upon cyclophellitol epoxide and aziridine covalent and
irreversible inhibitors representing a potent and widespread
approach. Such inhibitors for enzymes active on polysac-
charides are potentially limited by the requirement for
several glycosidic bonds, themselves substrates for the
enzyme targets. Here, it is shown that non-hydrolysable
trisaccharide can be synthesized and applied even to
enzymes with challenging subsite requirements. It was
found that incorporation of carbasugar moieties, which was
accomplished by cuprate-assisted regioselective trans-dia-
xial epoxide opening of carba-mannal synthesised for this
purpose, yields inactivators that act as powerful activity-
based inhibitors for α-1,6 endo-mannanases. 3-D structures
at 1.35–1.47 Å resolutions confirm the design rationale and
binding to the enzymatic nucleophile. Carbasugar oligosac-
charide cyclophellitols offer a powerful new approach for
the design of robust endoglycosidase inhibitors, while the
synthesis procedures presented here should allow adapta-
tion towards activity-based endoglycosidase probes as well
as configurational isosteres targeting other endoglycosidase
families.
Activity-based protein profiling is an emerging, powerful
technique for the functional dissection of enzymes, often in
complex milieu and frequently with major applications in
human health and biotechnology.[1] Consisting of three main
components, a reactive (typically electrophilic) warhead, a
targeting motif (largely reflecting the substrate specificity of the
enzymes) in question and a reporter group (typically a
fluorophore, biotin, or azide/alkyne handle for two-step label-
ling). ABPs have been used across many enzyme classes. In the
glycoside hydrolase/glycosidase field they have found particular
use. Pioneering work by Withers trapping long-lived covalent
glycosyl-enzyme intermediates was adapted by Vocadlo and
Bertozzi to label β-galactosidases and subsequently applied to
various glycosidases.[2–4] Of particular note, has been the
development of cyclophellitol epoxides and aziridines.[1,5] Build-
ing upon the Madsen synthesis,[6] such reagents have been
used to probe numerous exoglycosidase classes, frequently
those involved in lysosomal storage diseases including the
Gaucher GBA β-glucosidase,[7] the Pompe α-glucosidase,[8] α-L-
fucosidases,[9] β-glucuronidases,[10] α-L-arabinofuranosidases,[11]
and others. All of these cyclophellitol-derived inhibitors/probes
were based on monosaccharide scaffolds for “exo” glycosidases.
Very recently, the cyclophellitol concept has been extended to
endo-acting enzymes requiring disaccharide,[12] or longer target-
ing/ specificity motifs - compounds that proved synthetically
tractable by (Lewis) acid mediated glycosylations using partially
protected cyclophellitol epoxides or aziridines as the
acceptor.[13] Whilst this extends the potential enzyme range for
glycosidase ABPs considerably, as the requirement for addi-
tional saccharide units increases, so does the potential for the
ABP itself to become a substrate rendering data interpretation
more complex. Indeed, recent transposition of cyclophellitol
epoxides and aziridine ABPs to the biotechnology sector,
exemplified by endo-acting xylanases, did reveal hydrolysis of
the disaccharide probes (by exo-acting β-xylosidases) to yield a
functional monosaccharide ABP which could then inhibit β-
xylosidases giving rise to dual labelling of both endoxylanases
and exo-acting β-xylosidases in fungal secretomes.[12a] In this
case, interpretation could be aided by the use of competition
with exoglycosidase-specific inhibitors, but it clearly raises the
problems of using ABPs on endoglycanases generally, especially
those which require inhibitors longer than disaccharides
because of their complex subsite binding energies.
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The CAZy (www.cazy.org) family GH76 α-1,6 endo-
mannanases,[14] in many ways, highlight these challenges. GH76
enzymes catalyse the hydrolysis of α-1,6-mannans, such as
those found in the yeast cell wall, with net retention of
anomeric configuration.[15] In 2015 their 3D structure and
putative catalytic itinerary were identified revealing - in the
case of the Bacillus circulans enzyme - five enzyme subsites “-3
to +2” (using the described nomenclature)[17] with Asp124
acting as catalytic nucleophile and Asp125 as catalytic acid/
base in a classic Koshland double-displacement reaction.[16]
Observed  1 mannose distortion OS2 (Michaelis complex) and
B2,5 (man-isofagomine inhibitor) conformations implied a cata-
lytic itinerary OS2-[B2,5]
� -1S5 for the formation of the covalent
intermediate; a pathway supported by QM/MM metadynamics
simulations of the reaction pathway. Notably, however, both S-
linked disaccharides and 1,6-man-deoxymannojirimycin bound
in the  3 and  2 subsites and did not engage the catalytic
apparatus hinting at very strong, indeed dominating, interac-
tions at the  3 and  2 subsites which would challenge future
inhibitor design.[16,18] Subsequent attempts to obtain inhibitor
complexes of the B. circulans GH76 were indeed hindered both
by the domination of  3 and  2 to binding and the require-
ment for non-/poorly hydrolysable inhibitors in order to occupy
 3 to  1 subsites without degradation during prolonged
incubations.[18] This is especially important given that fungal
GH76 enzymes, implicated in transglycosylation involving
glycosylphosphatidylinositol anchors, are essential proteins and
therefore potential broad spectrum anti-fungal drug targets.[19]
We therefore thought GH76 α-mannanases would be a
challenging testbed system for oligosaccharide cyclophellitol
mechanism-based inhibitors.
Here, we report the design, synthesis and application of di-
and trisaccharide α-1,6-α-manno-cyclophellitol mechanism-
based inhibitors 1–3 (Figure 1). We show, notably through mass
spectrometry and high resolution 3-D structural analyses, how
the disaccharide cyclophellitol is indeed a poor inhibitor, but
how the trisaccharide versions, in particular the carbasugar-
stabilised one, potently inhibit B. circulans GH76. This work now
provides a strategy for the successful development and
application of oligosaccharide activity-based probes across a
broad range of polysaccharide utilising enzymes with complex
or stringent subsite demands.
Disaccharide analogues are rarely the optimal inhibitors for
endoglycosidases, but trisaccharide analogues, by virtue of their
length, are necessarily also substrates lessening their potential
for enzyme inhibition and application. Several strategies to
make non-hydrolysable extended inhibitors for endoglycosi-
dases have been described in the literature. Most classically
these involve the incorporation of non-hydrolysable S- or C-
“glycosidic” linkages,[20] although mis-matched stereochemistry,
such as in the case of the chitinase inhibitor allosamindin,[21] has
also been used but is totally dependent on the target enzyme
accommodating but not hydrolysing the incorrect sugar and
thus will not be generally applicable. In the case of GH76 α-
mannanases, not least because of the potential issues with S-
oligosaccharides described by Belz and colleagues,[18] we chose
to synthesise cyclophellitol di- and trisaccharides 1 and 2,
respectively, and to render the latter less hydrolysable through
the incorporation of a carba sugar moiety (as in 3). The
synthesis of di-and trisaccharides 1 and 2 follows general
procedures we have previously reported for the construction of
xylobiose and cellobiose cyclophellitols, and is based on the
preparation of partially protected cyclitol epoxides (and
aziridines) that subsequently are glycosylated using contempo-
rary glycosylation chemistries.[12a,b] Details on the synthesis of
compounds 1 and 2 can be found in the Supporting
Information. The synthesis of carba-trisaccharide cyclophellitol 3
necessitated the development of new methodology, which we
achieved as depicted in Scheme 1.
The key step in the synthesis is the copper(II) triflate
mediated regioselective opening of orthogonally protected 1,2-
deoxy-carbaglucose-1,2-epoxide 6, for which purpose we
adapted methodology recently reported by Di Bussolo and co-
workers.[22] Epoxide 6 needed for this purpose was prepared as
follows. TIPS protection of the primary alcohol in protected
Figure 1. 1,6-epi-manno-cyclophellitol di- and trisaccharides subject of the
here-presented studies. A (in disaccharide 1) denotes a possible exoglycosi-
dase cleavage site. B (in trisaccharide 2) denotes a possible endoglycosidase
cleavage site, which is stabilised in 3.
Scheme 1. Reagents and conditions: (a) i) TIPS Cl, imidazole, DMF, quant.; ii)
Li, naphthalene, THF,  78 to  20 °C; (b) i) m-CPBA, DCM,  20 °C to rt, 93%
over two steps; ii) BnBr, NaH, TBAI, THF, 0 °C to rt, 75%; (c) acceptor 7
(2 equiv.), Cu(OTf)2, toluene, 40 °C, 66%; (d) i) BzCl, pyridine, N-meth-
ylimidazole, DCM; ii) TBAF, THF, 70% over two steps; (e) donor 10, TMSOTf,
DCM,  30 °C, 1 h, 96%; (f) i) 1,1,1-trifluoroacetone, oxone, NaHCO3, EDTA,
H2O, MeCN, EtOAc, 0 °C, 75%; ii) NaOMe, MeOH, DCM, 83%; iii) Pd(OH)2/C,
H2, MeOH, dioxane, H2O, 85%.
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carba-glucal 4 and ensuing Birch debenzylation gave cyclo-
hexene 5.[23] Treatment of 5 with mCPBA in dichloromethane
led to stereoselective epoxidation as directed by the allylic
alcohol, and ensuing benzylation of the two secondary alcohols
gave epoxide 6 in good yield. Regioselective, trans-diaxial
nucleophilic opening of the epoxide in 6 with the primary
alcohol of partially protected manno-cyclohexene 7 (see for the
synthesis of 7 the Supporting Information) was effected under
the agency of a catalytic amount of Cu(OTf)2 under slightly
elevated temperature,[22] affording 8 in good yield and as the
single regioisomer observed. Protective group manipulations
then gave 9, which was glycosylated with mannosyl trichlor-
oacetimidate 10 (Scheme 1) to yield pseudo-trisaccharide 11 in
high yield. Epoxidation of the alkene in 11 using in situ
generated 1,1,1-trifluoro-dimethyldioxirane proceeded with
good yield and stereoselectivity. Global two-step deprotection
of both benzoyl esters and benzyl ethers finally gave target
trisaccharide cyclophellitol 3.
Armed with the 6-epi-manno-cyclophellitol di- and trisac-
charides 1–3, we next sought to study the inhibition and mode
of binding of these compounds in crystal structures of Bacillus
circulans GH76 (BcGH76).[16] We used a more easily crystallizable
variant, R341Q, designed to prevent formation of an intermo-
lecular salt bridge due to crystal packing and allow ligand
complex formation, but which is otherwise unchanged in
catalytic machinery and efficiency.[16] Details of X-ray structures
are given in Table 1 and Supporting Information Table S1.
Initial attempts to soak the α-1,6-α-manno-cyclophellitol
disaccharide 1 into crystals of a crystallization variant, R341Q, of
the “wildtype” enzyme (R341Q variant) yielded a complex with
density showing only the  3/-2 subsites occupied (not shown,
but similar to that seen in the  3/-2 sites for the trisaccharide
complexes below). A soak with the trisaccharide 2 revealed a
mixture of partially occupied trisaccharides and hydrolysed
disaccharide product, with the latter again occupying subsites
 3 and  2 (Supporting Information Figure S1). The refined
structure (whose interpretation was rendered far more facile
when subsequently viewed in Iight of the complexes D125 N
with 2 and 3, described below) showed low, partial, occupancy
by a covalently bound sugar in the  1 subsite with the C1
position refining to approximately 1.55 Å from the OD2
carboxylate oxygen of the nucleophile Asp 124. Further
examination of the electron density map calculated after
modelling the covalent species revealed the additional pres-
ence of an unreacted epoxide in the  1 subsite (Supporting
Information Figure S1). Given the clarity of density for an α-1,6
mannobiose in the  3 and  2 subsites, which was sufficient to
allow refinement of fully occupied disaccharide in these sites,
the presence of mixed di- and partial trisaccharide species
clearly highlights the challenges of the unmodified trisaccharide
inhibitor on this system.
In order to test our hypothesis about partial occupancy and
ligand hydrolysis, we harnessed the D125 N variant of BcGH76.
This is a variant of the catalytic acid/base which is inactive
against unactivated glycosides, but which we reasoned would
react with the 6-epi-manno-cyclophellitol epoxides, even if at a
reduced rate. Indeed, rapid (30 mins) soaking of 2 into these
D125 N crystals led to a partially occupied “disaccharide”
complex (density only really clear in  3 an  2, not shown), but
a 10-day soak (1 mM 2) produced a full occupancy covalent
adduct to the catalytic nucleophile Asp124, Figure 2a. This
complex shows that fully-reacted covalent adduct may be
formed when the enzyme is depleted in catalytic activity.
The trisaccharide binds in the  3 to  1 subsites, with
identical interactions to previous GH76 complexes in  3 and
 2. In the  1 subsite, the 6-epi-manno-cyclophellitol has
opened (or is at least subsequently observed bound) trans-
equatorially (as opposed to the more common transdiaxial
opening), Figure 2. The mannose ring is observed in 4C1 chair
conformation - one inconsistent with the proposed conforma-
tional pathway (OS2-[B2,5]
�-an intermediate initially in 1S5 con-
formation). Comparison of the covalent adduct here, with the
OS2 Michaelis complex (PDB 5AGD),
[16] shows that interactions at
the  3, and  2 subsites are identical. However, in the  1
subsite, the pseudo-sugar ring of the manno-cyclophellitol is
displaced from its position in the Michaelis complex with its
ring plane rotated greatly (beyond perpendicular) to that seen
in the natural substrate, to such an extent that the oxygens
equivalent to O3 and O4 actually lie 5–6 Å from their positions
observed for the Michaelis complex in a position that would
not be possible for a natural substrate (Supporting Information
Figure S2). Whilst other trapped cyclophellitols we have
Table 1. Details of BcGH76 complexes with 6-epi-manno-cyclophellitol di-
and trisaccharides 1–3. Full details in Table S1.
D125 N (2) D125 N (3) WT[a] (3)
Resolution 1.40 Å 1.47 Å 1.35 Å
PDB Code 6ZBW 6ZBM 6ZBX
[a] WT and D125 N crystals refer to an R341Q variant (with WT active site
residues) and D125 N/R341Q respectively.
Figure 2. Fo Fc “omit” electron density for the 6-epi-manno-cyclophellitol
“trisaccharide” 2 and 3 bound to BcGH76. (a) 2 bound to D125 N variant, (b)
3 bound to 125 N (c) carbacycle-containing “trisaccharide” 3 bound to the
WT enzyme. Contour levels are 3 r.m.s.d. (0.46, 0.52, and 0.45 e Å 3,
respectively).
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observed appear in conformations and positions consistent
with the known itineraries of the enzymes, this is not the case
here.
Having shown that a trisaccharide inhibitor would bind
successfully when the enzyme was inactive for normal
hydrolysis, we then sought to study the binding of the
trisaccharide 3, which we postulated would be non-hydro-
lysable by virtue of containing a central carbacycle, to both WT
and, as a control, D125 N enzymes. Compound 3 indeed bound
to D125 N in an identical manner to 2, Figure 2B. Crucially, in
marked contrast to 2, on catalytically active WT enzyme the
bespoke carbacycle-containing “trisaccharide” 3 covalently
bound to the WT enzyme at full occupancy, Figure 2C,
confirming that non-hydrolysable inhibitors for complex endo-
active enzymes can be designed successfully.
Compounds 2 and 3 both make identical interactions to
BcGH76 (see Figure 3 for that of 3 and the Supporting
Information for 2). As with reported complexes involving
competitive inhibitors, interactions in the  3 and  2 subsites
are mainly via hydrogen bonds with Trp172, Asn181, Asp228,
Arg229, Asp239, and Tyr243. As described above, the  1 sugar
is in 4C1 chair conformation with the sugar flipped out of the
active centre and making none of the interactions seen for the
Michaelis complex (5AGD) or the previously reported man-
isofagomine complex (PDB 4D4D).
Although crystal structures are clearly indicative that the
carbacycle containing inhibitor 3 reacted, as expected, with the
wild-type enzyme, and that 2 only reacts well with the D125 N
variant, we sought to verify these structural observations
through mass spectrometry in solution. We therefore analysed
the molecular weights and relative weight distribution of
BcGH76 proteins incubated with probes 1–3. To this end, two
non-variant WT and mutant construct versions (WT-BcGH76,
BcGH76-D125 N) were used, as well as the two R341Q variants
used for the above structural studies (“WT” BcGH76-R341Q and
the double mutant, BcGH76-D125 N/R341Q) with each of the
three probes at a probe-protein concentration ratio of 10 :1 in
25 mM HEPES buffer at pH 7 with 100 mM NaCl for 16 to 22 h
at 293 K. The results are depicted in Table 2 with the numbers
indicating the relative amount of protein that has reacted with
the respective probe (total protein count 100%).
These data confirm results from the crystallisation studies
that carba-trisaccharide 3 is the most effective and ‘clean’
inhibitor of the set. Both the wild-type enzyme (BcGH76) and
non-catalytic mutant (BcGH76-R341Q) reacted to form the
enzyme-probe adduct with 100% efficiency. Both disaccharide
1 and trisaccharide 2 react much less efficiently, with maximally
30% conversion to the enzyme-probe adduct for both these
enzymes. These results strongly support our initial hypothesis
that, where disaccharide inhibitors are too small to optimally
occupy multiple substrate binding sites, non-stabilized trisac-
charide inhibitors may fall prey to enzymatic processing to yield
non-inhibitory products.
From the experiments incubating the two catalytic acid/
base mutants, BcGH76-D125 N and BcGH76-D125 N/R341Q,
disaccharide probe 1 proved unreactive likely reflecting
impaired binding to the variant. Probes 2 and 3, likely because
of their enhanced active site affinity, do react to yield covalent
adducts, data supporting the co-crystal structure obtained from
the complex of 3 and BcGH76-D125 N. The difference in the
efficiency of opening the epoxide in probes 2 and 3 by the
catalytic nucleophile (D124) in the mutant enzymes, as opposed
to the wild-type, is likely caused by the absence of the catalytic
acid-base. We have previously found that mechanism-based
retaining exoglycosidase inhibitors may still react with mutant
enzymes with the catalytic acid-base substituted, even while
such enzymes are catalytically inactive and ascribe this
phenomenon to the enhanced intrinsic reactivity of an epoxide
(or related electrophile) compared to an interglycosidic acetal
linkage. This reasoning may in fact also explain the at a first
glance counterintuitive result that inhibitor 2 reacts more
efficiently with the acid-base variants than 3 - the opposite
result from the experiments with the two wild-type (with
respect to the active site) enzymes. Arguably, the active site
mutants are not able to hydrolyse the glycosidic linkage
connecting the manno-disaccharide in 2 with the manno-
cyclophellitol. In this scenario, which supports our design,
nucleophilic opening of the epoxide remains as the only option
for the mutant enzymes, whereas the wild-type ones have an
alternative pathway in processing the endoglycosidic linkage.
In summary, we have described the rational design of an
effective endomannosidase trisaccharide inhibitor composed of
two carbasugars: one bearing an epoxide at the reducing end
that acts as the electrophile for covalent, irreversible inhibition
and one taking up position of an internal mannosides to protect
the construct from endomannosidase mediated hydrolysis. For
this purpose, we developed a concise and effective route of
Figure 3. Interactions of the carbacycle (blue) within the 6-epi-manno-
cyclophellitol “trisaccharide” 3 with WT BcGH76.
Table 2. Percentage of reacted mannanases with the respective probes
after 16 or 22 h of incubation. Both wild-type and non-catalytic mutant
(R341Q) are fully transformed into the covalent enzyme-inhibitor adduct
with stabilised trisaccharide 3, but not with inhibitors 1 and 2.
Protein 16 h incubation 22 h incubation
1 2 3 1 2 3
Wild Type 25 30 100 30 30 100
D125 N 0 75 40 0 85 44
R341Q 25 17 100 30 17 100
D125 N/R341Q 0 75 40 0 85 45
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synthesis that moreover is flexible for adaptation towards
analogous tri-and oligosaccharidic structures. Variation of
substitution pattern and configuration of electrophile 6 and
nucleophile 7 in Scheme 1 should allow for the construction of
inhibitors targeting other retaining endoglycosidase families,
whereas endowing either the reducing end sugar analogue (by
replacing the epoxide oxygen with a substituted aziridine
nitrogen) or the non-reducing end sugar with a reporter entity
(biotin, fluorophore) will open up activity-based endoglycosi-
dase profiling studies. Our results thus prove our working
hypothesis to bear out: effective mechanism-based endoglyco-
sidase inhibitors can be designed taking into account stabiliza-
tion of internal glycosidic linkages through the employment of
carbacyclic entities. These results underscore literature findings
on competitive endoglycosidase inhibitors and our design and
synthetic methodologies may also find application in the design
of such entities. Our own research focuses on the design of
inhibitors and activity-based probes for a range of endoglycosi-
dase families and chemistries and designs, as reported here, will
be implemented in these studies.
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